NervGen Pharma delivers “gold standard” in clinical trial, says iA Capital - Cantech Letter
7/29/2022 12:00:00 AM3 years 7 months ago
by Jayson MacLean
by Jayson MacLean
In a new report on Friday, Stellick reiterated her “Speculative Buy” rating on NervGen Pharma, saying the company could have over a $10 billion annual market ahead of it for its lead drug candidate.
The stock just got a big boost from new clinical results, and that bodes well for fans of NervGen Pharma (NervGen Pharma Stock Quote, Charts, News, Analysts, Financials TSXV:NGEN), according to iA Ca… [+5042 chars]
full article...